Development of an effective mucosal vaccine to induce specific immune responses against Foot-and-mouth disease virus (FMDV). For this purpose, the FMDV VP1 gene (SPVP1) was optimized and synthesized based on the codon bias of Lactococcus lactis (L. lactis), and then incorporated in the plasmid pNZ8148. L. lactis NZ9000 containing the pNZ8148-SPVP1 recombinant plasmid was used as an oral delivery vehicle to induce anti-FMDV mucosal and systemic immune responses in mice. After confirmation that the SPVP1 protein was expressed successfully in the recombinant L. latic, the mice were orally challenged with NZ9000-pNZ8148, NZ9000-pNZ8148-SPVP1, phosphate-buffered saline as a mock infection group, or with inactivated vaccine as a positive group. Mice immunized with NZ9000-pNZ8148-SPVP1 produced high levels of mucosal secretory IgA (sIgA), antigen-specific serum IgG, IgA, and neutralizing antibodies, and developed stronger cell-mediated immune reactions and significant T spleen lymphocyte proliferation. Furthermore, the recombinant group generated much higher levels of IFN-γ, IL-2, IL-4, IL-5, and IL-10 than the other groups. Potent immune responses were successfully elicited in mice with FMDV VP1 delivered through L. lactis.

中文翻译：

---

小鼠对口蹄疫病毒重组乳酸乳球菌口服疫苗的免疫反应

开发有效的粘膜疫苗以诱导针对口蹄疫病毒 (FMDV) 的特异性免疫反应。为此，基于乳酸乳球菌（L. lactis）的密码子偏倚对FMDV VP1基因（SPVP1）进行了优化合成，然后将其整合到质粒pNZ8148中。含有 pNZ8148-SPVP1 重组质粒的乳酸乳球菌 NZ9000 被用作口服递送载体，以在小鼠中诱导抗 FMDV 粘膜和全身免疫反应。确认SPVP1蛋白在重组乳酸乳杆菌中成功表达后，小鼠口服NZ9000-pNZ8148、NZ9000-pNZ8148-SPVP1，磷酸盐缓冲液为模拟感染组，灭活疫苗为阳性组。 . 用 NZ9000-pNZ8148-SPVP1 免疫的小鼠产生高水平的黏膜分泌型 IgA (sIgA)，抗原特异性血清 IgG、IgA 和中和抗体，并产生更强的细胞介导免疫反应和显着的 T 脾淋巴细胞增殖。此外，重组组产生的 IFN-γ、IL-2、IL-4、IL-5 和 IL-10 水平远高于其他组。通过乳酸乳球菌传递的 FMDV VP1 小鼠成功引发了有效的免疫反应。